Positive results from Immunoscore® study presented at ASCO 2016

Jun 7, 2016

Dr Jérôme Galon, Research Director at Inserm, Head of the laboratory of Integrative Cancer Immunology, Paris, France, and Scientific Advisor of IO Biotech presented at ASCO 2016 the very positive results of the international initiative, the Immunoscore® study. The assay was developed to predict the ability of a person’s immune system to fight tumor cells and its performance has already been documented in a number of studies for its ability to predict recurrence in colon cancer.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial